PTPN18 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL13855917	0.77	1/20
SCHEMBL13855929	0.76	1/20
SCHEMBL4670417	0.74	1/20
SCHEMBL4670420	0.74	1/20
SCHEMBL14922088	0.71	1/20
SCHEMBL14922106	0.71	1/20
SCHEMBL14104225	0.70	1/20
SCHEMBL13856602	0.69	1/20
SCHEMBL13856618	0.69	1/20
SCHEMBL14104317	0.69	1/20
SCHEMBL13856552	0.69	1/20
SCHEMBL13856659	0.69	1/20
SCHEMBL13856447	0.68	1/20
SCHEMBL14104277	0.67	1/20
SCHEMBL13856628	0.66	1/20
SCHEMBL14104194	0.66	1/20
SCHEMBL31541587	0.66	1/20
SCHEMBL14001421	0.66	1/20
SCHEMBL13856506	0.66	1/20
SCHEMBL13855954	0.65	1/20

Clinical trials — most relevant to PTPN18 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance	PHASE4	UNKNOWN
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Pembrolizumab And Tamoxifen Among Women With Advanced Hormone Receptor Positive Breast Cancer And Esr1 Mutation	PHASE2	UNKNOWN
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Rechallenge With Panitumumab Driven by RAS Dynamic of Resistance	PHASE2	COMPLETED
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease	PHASE2	COMPLETED
An Exploratory Study on the Use of Ipalotinib (Tislelizumab) Combined With Sunitinib and Olaparib for Neoadjuvant Therapy in HRD-positive Advanced Ovarian Cancer	PHASE2	RECRUITING
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Immunoregulatory Therapy for 2019-nCoV	PHASE2	UNKNOWN
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
A Study of HMPL-415S1 in Patients With Advanced Malignant Solid Tumors	PHASE1	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Role of NFKBIA and PTPN22 Genes Polymorphism in Acute Rejection Susceptibility After Living Donor Liver Transplantation in Egyptian Patients.	nan	COMPLETED
Immunophenotypic Evaluation of CD305 and CD85d in B-Cell Lymphoid Neoplasms	nan	NOT_YET_RECRUITING
Monitoring of Breathing Effort Through Pressure Time Product Measurement Using Airway Occlusion Pressure	nan	UNKNOWN
Modulatory Effect of Prodigiosin or Pioglitazone on TIME and the Crosstalk to Immune-Checkpoint Protein(s)	nan	NOT_YET_RECRUITING
Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA	nan	RECRUITING
Clinical Study on the Application of PET Probes Targeting DDR2 in the Diagnosis of Interstitial Lung Disease With Cognitive Impairment	nan	NOT_YET_RECRUITING
What is the Impact of TKI on Thyroid Function in CML Patients?	nan	NOT_YET_RECRUITING
rT3 and Inflammation in Hashimoto's Thyroiditis	nan	COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma	nan	COMPLETED
Cardiovascular Effects of Empagliflozine	nan	UNKNOWN
Resistance to Immunotherapy in Gastric Cancer	nan	UNKNOWN
Is T-lymphocyte Calcineurin Phosphatase Up-regulated by Treatment With Tacrolimus?	nan	COMPLETED
Expression of CD19 Complex in Lymphoproliferative Disorders	nan	UNKNOWN
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a PTPN18 binder may also engage these)

Protein	Name	Similarity
Q61152	—	1.000	Q61152 →
PTPN7	Tyrosine-protein phosphatase non-receptor type 7	0.979	landscape →
O54838	—	0.974	O54838 →
Q4QQV2	—	0.972	Q4QQV2 →
GRB7	Growth factor receptor-bound protein 7	0.971	landscape →
CDC42BPG	Serine/threonine-protein kinase MRCK gamma	0.971	landscape →
RNF31	E3 ubiquitin-protein ligase RNF31	0.971	landscape →
B5DFA1	—	0.970	B5DFA1 →
O15211	—	0.970	O15211 →
B2RYG7	—	0.970	B2RYG7 →
Q9BYX2	—	0.970	Q9BYX2 →
P49445	—	0.970	P49445 →
P70218	—	0.969	P70218 →
Q99ML2	—	0.969	Q99ML2 →
Q9BXL6	—	0.969	Q9BXL6 →
DUSP5	Dual specificity protein phosphatase 5	0.969	landscape →
Q924T7	—	0.969	Q924T7 →
P55146	—	0.969	P55146 →
Q9R011	—	0.969	Q9R011 →
Q5TJE5	—	0.969	Q5TJE5 →
PLK3	Serine/threonine-protein kinase PLK3	0.969	landscape →
TNK1	Non-receptor tyrosine-protein kinase TNK1	0.969	landscape →
Q9PW71	—	0.969	Q9PW71 →
A7MBB8	—	0.968	A7MBB8 →
Q80XI6	—	0.968	Q80XI6 →
Q0QWG9	—	0.968	Q0QWG9 →
Q16829	—	0.968	Q16829 →
Q14807	—	0.967	Q14807 →
Q8WWN8	—	0.967	Q8WWN8 →
Q9UJY4	—	0.967	Q9UJY4 →